BK vs LFCR · P/E 17, $94.14B cap vs rev $75.5M
The Bank of New York Mellon Corporation (BK) versus Lifecore Biomedical Inc. (LFCR) — a side-by-side from cached financials, not a winner call.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Lifecore Biomedical Inc. (LFCR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
BK does not have a complete income-statement cache yet.
Latest reported LFCR revenue for 2025-12-31 was $75.5M. Net income was -$18.0M. Revenue was up 771.6% from 2025-06-30 to 2025-12-31. LFCR currently screens at market cap $207.1M.
BK currently screens at market cap $94.14B and trailing P/E 17.0. LFCR currently screens at market cap $207.1M.
Not investment advice. Open the BK and LFCR stock pages for the full models.
Not investment advice.